Molecular Partners: Building Tomorrow s Breakthroughs. Corporate Presentation Molecular Partners AG, Switzerland (SIX: MOLN) February 7, 2019
|
|
- Madeline Sullivan
- 5 years ago
- Views:
Transcription
1 Molecular Partners: Building Tomorrow s Breakthroughs Corporate Presentation Molecular Partners AG, Switzerland (SIX: MOLN) February 7,
2 Molecular Partners: A Swiss Biotech developing innovative protein drugs $ DARPin ENGINE DARPin PIPELINE TEAM WORK CAPITAL DARPin platform as source of mono/multi-specific protein drugs Rapid cycle of innovation to test novel therapeutic design Validation in >1.8k patients treated to date (mainly Abicipar) Abicipar: Phase 3 in wet AMD : Phase 2 in MM and NSCLC MP0274: Phase 1 in Her2 positive cancer indications MP0310: First-in-human in multiple cancer indications in co-workers purpose driven, evolutionary organization Partnership with Allergan on Abicipar, ophthalmology assets New partnership with Amgen on MP0310 Multiple near-term catalysts with significant value creation potential Well financed: on-track to steady income with Abicipar launch (2020e) 2
3 Key Achievements in 2018 Abicipar as first & only fixed 12-week anti-vegf namd supported by P3 data Further optimized material in clinical testing for reduced inflammation (MAPLE) shows initial activity in MM to revert adaptive resistance to PIs I/O DARPin toolbox: 1st development candidate MP0310 on track to FIH New partnership with Amgen (MP0310) Further strengthening of oncology team on all levels MP research organized into specific focus areas to support pipeline growth 3
4 DARPin Proteins: Nature s Choice for Multi-Specific Binding MONOCLONAL ANTIBODIES DARPin Protein(s) Binding regions / specificity DARPin module Binding region / specificity 15 kda SCALE 150 kda Multi-DARPin product candidate High affinity and specificity Low immunogenicity potential Large size: 150 kda Tunable half life Small size: 15 kda (1/10 of monoclonal antibody) Complex architecture: 4 proteins with 12 domains Target binding via flexible surface loops (CDRs) Simple architecture: 1 protein with 1 domain Target binding via rigid surface structure 4
5 DARPin Engine to Select Therapeutic Designs that Match Desired Function DARPin module selection DARPin Library with modules Opening novel Therapeutic Design Space Selecting the «optimal» Therapeutic Design Target(s) Identified DARPin modules with high target affinity Multi-DARPin product candidates Therapeutic Design matches its function 5
6 Evolution of Therapeutic DARPin Designs Abicipar MP0274 MP0310 Mono-Antagonist Multi-Antagonist Allosteric Modulator Tumor-local agonist «T cell switch» Long-acting VEGF inhibitor in the eye Blocking 2 key escape pathways in parallel Molecular handcuff inducing cell death in HER2+ cancer cells Tumor-restricted activity to avoid dose-limiting side effects First fixed 12 week ocular injection interval Overcome adaptive resistance to SOC Activity in patients not benefiting from SOC Opening a therapeutic window for combinations 6
7 Ophthalmology DARPin Engine: Source of Product Candidates I/O Oncology A Balanced and Robust Portfolio Product Candidates Indication/ Focus Preclinical Phase 1 Phase 2 Phase 3 Commercial Rights Multiple Myeloma, PI combo Multiple Myeloma, IMiD study EGFR-mutated NSCLC MP0274 HER2 positive MP0310 Additional proprietary DARPin candidates FAP x 4-1BB Various in I/O Abicipar Neovascular AMD Abicipar Additional DARPin candidates DME Various in Ophthalmology AMD: age-related macular degeneration; DME: diabetic macular edema; NSCLC: non-small cell lung cancer 7
8 Program Deep Dive: Abicipar, MP0274, MP0310 8
9 Abicipar has Potential to be First Fixed 12 Week anti-vegf Abicipar Choroidal Neovascularization Medical Need: current anti-vegfs in namd are mostly dosed monthly or extended to bi-monthly, leading to high patient burden and under-dosing in real-world settings OCT in namd MoA: Abicipar is the only long-acting anti-vegf and has shown to be the first fixed 12-week namd drug, lowering patient burden given full effectiveness in real world setting Status: Allergan plans FDA filing in H and launch in 2020 and plans to start DME Phase 3 in H VA defect in namd Source: Allergan presentation, 06 Dec 2018, VA visual acuity, OCT optical coherence tomography 9
10 Abicipar Phase 3 Efficacy Results (SEQUOIA study, 1yr data) Secondary Endpoint: Change in BCVA From Baseline Abicipar Q8 and Q12 in SEQUOIA Non-Inferior to Ranibizumab Primary Endpoint: STABLE VISION Abicipar Q8 and Q12 Non-Inferior to Ranibizumab Q4 Source: Allergan July, 2018 and October 2018 Secondary Endpoint: Change in CRT similar across in all groups 10
11 Abicipar Outlook: Abicipar on track for expected 2020 launch Primary and secondary endpoints support abicipar potential to become the first fixed 12-week anti VEGF in namd Overall safety events between abicipar and ranibizumab were comparable Intraocular inflammation potential was higher for Abicipar (15%) vs ranibizumab (< 1%) Majority of inflammation was mild to moderate and were treated with topical corticosteroids Further optimized Abicipar material was produced and is currently being tested in a clinical trial (MAPLE) Results H
12 : Our First Multi-DARPin Product Candidate HSA DARPin HGF DARPin VEGF DARPin HSA DARPin Medical Need: Some tumors develop adaptive resistance to SOC by up-regulating VEGF and HGF Upregulation of escape pathways after SOC Medical need: Agents that block escape pathways to SOC MoA: inhibits both VEGF and HGF simultaneously Blocking these adaptive escape pathways may restore clinical sensitivity to SOC HGF (c-met) VEGF HGF (c-met) VEGF Status: Phase 2 in MM and EGFR-mut NSCLC SOC, standard of care; HSA, human serum albumin. 12
13 Phase 1 Results Validate DARPin Platform as Systemic Anticancer Agents Safe, convenient dosing, with clear signs of efficacy even on stand-alone basis PATIENT POPULATION: Solid tumor patients refractory to SOC Dosing Convenient, flexible administration Exposure Favorable exposure Safety Well tolerated Efficacy Clear signs even stand alone Well tolerated Dosing every 2 or 3 weeks Half-life ~2 weeks Convenient 1 hr infusion Trial dosage: 8mg/kg every 2 weeks or 12mg/kg every 3 weeks Sustained drug exposure over multiple cycles (up to >1 year) Low immunogenicity (only 2 out of 42 patients with relevant 1 increase in ADA titers) AEs as expected for any VEGF inhibitor Hypertension most frequent AE, observed in approx. 2/3 of patients, with grade 3 in about 1/3 of patients SAEs (in > 1pt) were nephrotic syndrome (4pt), venous thromboembolism (3pt), anemia (2pt) and dyspnea (2pt) Significant reduction in tumor volume in two patients Treatment duration (% of patients): 3 months for 40% 6 months for 10% 1. More than 20-fold above background, no demonstrable effect on PK 13
14 : Potential to Treat Several Indications MM and EGFR-mut NSCLC selected initially Head and neck squamous cell EGFR-mutated NSCLC Multiple myeloma Hepatocellular carcinoma Colorectal cancer Nasopharyngeal Gastric cancer Renal cancer Anal cancer INCIDENCE: 1 <50,000 50, ,000 >100,000 1) Including US/5EU/JP. Datamonitor. 14
15 Unmet Medical Need in Multiple Myeloma (MM) Illustrative course of disease of a MM patient 1 IMiD or PI PI or IMiD PI + our «initial» trial MM remains incurable for most patients as cells acquire adaptive resistance to currently available therapies Relapse inevitable Time to relapse shortens with every treatment cycle Quality of response tends to diminish 15 1) Hajek, R. Strategies for the Treatment of Multiple Myeloma in 2013: Moving Toward the Cure. In Multiple Myeloma: A Quick Reflection on the Fast Progress (2013).
16 Activated -c-met receptor HGF/c-Met Upregulation in Refractory/Relapsed Multiple Myeloma Dynamic activation of the HGF pathway during disease progression 1. HGF is highly overexpressed in bone marrow biopsies of multiple myeloma patients Newly diagnosed On partial remission Relapsed 28% 2% 89% Bone marrow tumor Score 3+ 6/8 patient samples c-met c-met c-met Bone marrow tumor Score 2+ 2/8 patient samples Solid tumor Score 1+ 0/8 patient samples High HGF levels in serum is a poor prognostic factor in multiple myeloma 2 1. Moschetta M, et al. Clin Cancer Res 2013;19: Wader K.F. et al, Eur. J. Haematol
17 Tibia Muscle Volume at Termination (mm 3 ) Tibia Muscle Volume at Termination (mm 3 ) can be combined with either PI or IMID backbone for MM 5 5 X-ray bone lysis score 4000 Muscle Invasion Bone Lysis & Proteaosome Inhibitor (Velcade ) & IMiD (Pomalyst ) X-ray Bone Lysis Scores vehicle Velcade + Velcade Vehicle Pomalyst + Pomalyst vehicle Velcade + Velcade 0 Vehicle Pomalyst + Pomalyst Graphs present mean and standad error of mean 17
18 Expansion Cohort 1 Phase 2 Study in MM: Promising Signs of Efficacy * * * Patient population: Patients with MM with 2 prior lines of treatment, including IMiD and PI, and no response or early relapse Treatment regimen: Velcade /Dexamethasone plus * 5 of 8 patients with objective responses (cohort 1) 3 of 4 patients coming directly from a PI-based regimen responded (*) (cohort 1) Durable remission observed in heavily pretreated patients (8mg/kg) combined with Velcade has shown tolerable safety profile Study ongoing with additional patients ( ) Treatment duration (weeks) Very Good Partial Response Partial Response Minor Response Stable Disease Progressive Disease On Treatment Data cut-off: 31 January dose level: 8mg/kg/3weeks. 18
19 has the Potential to Overcome Adaptive Resistance Patients coming directly from PI Patients coming directly from IMiD Weeks Weeks Three out of four patients coming immediately from a PI-based regimen responded has potential to overcome adaptive resistance mechanism Amend trial on these patients only Two out of four patients coming from IMiDbased regimen responded Relative contribution of versus class switch (PI IMID) to be determined Initiate new trial with plus IMiD for these patients Very Good Partial Response Partial Response Stable Disease Progressive Disease On Treatment Data cut-off: November 02,
20 Positioning in MM and Our «planned» Trials Multiple myeloma: 2nd most common blood cancer 1st Line Therapy n >100, nd Line 3rd Line n 30, th Line Global market value of MM treatment: $13 billion expected to exceed $20 billion by % 25% IMiD or PI + mab Transplant PI or IMiD + mab PI + IMiD + (CAGR: 13%) 1 has the potential to become backbone for later lines of treatment our «planned» trials 1. Including US/5EU/JP. Datamonitor, August
21 Unmet Need in EGFR-mutated NSCLC EGFRmutation T790 - mutation HGF up-regulation/ cmet pathway activation other - mutations No targeted drug approved for patients progressing on Tagrisso treatment high unmet medical need cmet- amplification ~10% Phase 2 ongoing in the US TREATMENT OPTION 1 1st Line: 1st Generation TKI 2nd Line: Tagrisso 3rd Line: Chemotherapy Patient population: Patients with EGFR-mut NSCLC who have failed to respond to Tagrisso TREATMENT OPTION 2 PFS: ~10.2 months Tagrisso PFS: ~8.5 months Chemotherapy Treatment regimen: Tagrisso plus PFS: ~18.9 months PFS-based data from the FLAURA and AURA3 study; TKI, Tyrosine Kinase Inhibitor 21
22 Unique Potential of in EGFR-mut NSCLC Treatment option 1 1st Line Therapy n=35,000 1 n=20,000 1 n 15, nd Line Iressa or Tarceva Tagrisso 3rd Line Tagrisso + 4th Line Global market value (EGFR NSCLC): ca. $2.8 billion expected to exceed $3.5 billion by 2023 (CAGR: 5%) 1 Treatment option 2 Tagrisso Tagrisso + P2 Trial No targeted drug approved after patients progress under Tagrisso treatment 1. Including actively treated, Stage IIIb and Stage IV prevalent cases in US/5EU/JP. Datamonitor, August 2018; Tang et al Oncotarget 2016: Activating EGFR mutations are found in ~40% (Asia), ~20% (US), and ~15% (EU) 22
23 NSCLC trial Summary No targeted drug approved for patients progressing on Tagrisso treatment Patients with EGFR-mut NSCLC who have failed to respond to Tagrisso Treatment regimen: Tagrisso plus Phase 2 in the US Initial cohort recruitment ongoing To date no new safety signals identified 23
24 MP0274: Killing HER2+ Cells by New MoA MP0274 Her2 «Open» HSA DARPin HER2 DARPin A HER2 DARPin B HSA DARPin Medical need: despite good antibody-based HER2+ treatments, eventually patients progress MP0274 Bi-paratopic DARPin Novel mode of action: MP0274 is an allosteric inhibitor blocking HER2- and HER3 signaling and inducing apoptosis No need for drug conjugation (ADC) for direct tumor cell killing Status: Phase 1 dose escalation in HER2 positive tumor patients that have progressed on SOC ongoing; Recruitment of first patient cohort completed MP0274 locks Her2 into fully inactive conformation Her2 «Locked» Apoptosis: Tumor cell suicide 24
25 % Killing MP0274 is a Highly Potent Tumor Cell Killer MP Tumor Cell Apoptosis BT474 MP Tumor Cell Killing BT474 MP0274 Ado-trastuzumab emtansine (Kadcyla ) [nm] Trastuzumab/ Pertuzumab (Herceptin / Perjeta ) New MoA may help patients who do not adequately respond to current therapies [nm]
26 Our Vision to Expand the Therapeutic Window Through Tumor-Localized Immune Modulation MP0310 Current IO therapeutics that activate the immune system (agonists) throughout the body show systemic side effects that can limit the effective dosing activated T cell healthy cells tumor cells Tumor-localized IO therapeutics that activate immune cells preferentially within the tumor may both increase efficacy and reduce systemic toxicities resting T cell activated T cell tumor stroma tumor cells 26
27 Localizer DARPin Toolbox: Tumor-Localized Immune Modulators MP0310 Tumor-localized immune modulators overcoming the limitation of systemic side effects Immune Modulator Solid Tumor TAA* Tumor Stromal Antigen Hematologic TAA OX BB CD40 Other Targets TAA x 4-1BB FAP x 4-1BB MP0310 FAP x CD40 TAA x OX40 TAA x 4-1BB TAA x CD40 *Tumor-Associated Antigen (TAA) 27
28 MP0310 (FAP x 4-1BB): Activating T-cells in the Tumor MP0310 Immune modulator Localizer Half-life extender MP0310 DARPin modules + + Illustrative graphic 4-1BB DARPin FAP DARPin HSA DARPin Medical need: most current 4-1BB agonists activate T-cells and NK cells systemically and are limited by side-effects MoA: MP0310 uses binding to FAP a tumor stromal target to cluster and activate T-cells primarily in the tumor + MP0310 Status: MP0310 is in preclinical development and partnered with Amgen. Phase 1 to start in H HSA, human serum albumin. 28
29 Mean tumor volume (mm 3 ) Number of hcd8 T cells per 0.2 g tumor Combined Therapy with MP0310 and TAA x CD3 Bi-Specific Results in Significant Increase of Intratumoral CD8+ T Cells MP0310 FAP-Mediated Tumor Accumulation of MP0310 HT-29-T-implanted NSG mice Tumor growth inhibition PBMC humanized HT-29 xenograft model Intratumoral CD8 T cells 2000 Vehicle *** Tumor 1500 TAA x CD3 TAA x CD3 + MP ** no-fap x 4-1BB mfap x 4-1BB Treatment days 0 Vehicle TAA x CD3 TAA x CD3 + MP
30 DARPin Strategy in Oncology Antigen-presenting cells, T cells PRIME & ACTIVATE Localized Immune Modulators MP0310 PRIME & ACTIVATE T cells ENGAGE Cytotoxic Immune Cells Tumor cells DIRECT KILL Direct Tumor Cell Killing ENGAGE Immune Cell UNBLOCK Tumor / Stromal cell interactions MODULATE Tumor Microenvironment Modulators T cells UNBLOCK Checkpoint Approaches MP0274 Tumor Cells DIRECT KILL MODULATE Tumor Stroma Cells 30
31 Partnerships 31
32 Molecular Partners Partnering Strategy Strategic Partnerships to leverage the potential of the DARPin platform& assets Broadened and accelerated clinical trials to maximize patient value Significant potential as funding source to cross-finance proprietary pipeline Allergan partnership to leverage the DARPin Candidates in ophthalmology Amgen partnership to test MP0310 in combinations with other IO drug candidates, especially T-cell engaging bi-specific antibodies Astra Zeneca collaboration to test combination with Tagrisso in EGFR-mut NSCLC (no rights attached) 32
33 Strategic Collaboration with Allergan in Ophthalmology Collaboration Structure Exclusive license agreement on Abicipar in retinal diseases Discovery alliance on three additional DARPin Candidates in ophthalmology Abicipar Financials Total of USD 360m in potential future milestones USD 210m development milestones pre-launch in namd & DME (targeted 2020 ff.) Additional USD 150m sales-based milestones Tiered royalties: Low double-digit to mid-teens Attractive >USD 8 billion market Eylea demonstrated that reduced injection frequency can lead to rapid market uptake 33
34 Strategic Collaboration with Amgen to Develop MP0310 Collaboration Structure: Collaboration and license agreement for development of MP0310 molecule (FAP x 4-1BB) Co-funding of clinical development: Parties will share costs in defined % for the first 3 indications subject to certain conditions For all additional clinical trials, Amgen will take over all development costs MP retains rights to develop and commercialize its own pipeline products in combination with MP0310 Financials: USD 50mio upfront payment USD 497mio in clinical, regulatory and commercial milestones Double digit, tiered royalties up to the high teens 34
35 Conclusions and Outlook 35
36 Investment Case DARPin Engine: Source for candidates with novel therapeutic designs Advanced and balanced DARPin Portfolio Abicipar in pivotal trial with potential to be first fixed 12-week anti VEGF in namd with Allergan s targeted launch approaching Clinical oncology pipeline with in phase 2 and MP0274 in phase 1 Research in oncology focus areas set-up to deliver highly innovative designs of candidates Organizational focus on product innovation and company growth Partnerships to accelerate development of DARPin candidates Well financed and on-track towards steady income with Allergan s expected Abicipar launch in
37 Accelerating Progress in 2019 and Beyond Abicipar BLA filing planned (H1) DME: P3 start MAPLE: results of further optimized material (H1) Additional data: ongoing P2 MM trial Start of P2 PI and IMiD-combo trial in MM Interim results from P2 NSCLC trial namd Launch Interim P2 data: PI-combo trial Interim P2 data: IMiD-combo trial MP0274 First safety & interim efficacy data MP0310 FIH with MP0310 (mono therapy) MP0310 combination trials Research Advance DARPin candidates Establish novel therapeutic designs Capital Funding into H (excl. any abicipar related proceeds) 37
38 Appendix 38
39 EXECUTIVE MANAGEMENT BOARD OF DIRECTORS Experienced Management Team & Board of Directors Dr. Patrick Amstutz, CEO Co-founder, former CBO & COO Member of the Board of Directors PhD in molecular biology from UZH Bill Burns, Chairman Former CEO of Roche Pharmaceuticals Former board member of Roche, Genentech, Chugai Pharmaceuticals, Shire Dr. Andreas Harstrick, CMO, MD 30 years of experience in oncology Developed multiple mab oncology products Senior positions at Merck-Serono, Imclone, Eli Lilly Dr. Michael Stumpp, COO Göran Ando, Vice Chairman Former Chairman, Novo Nordisk Former CSO, Pharmacia Gwen Fyfe Former VP, Oncology Development at Genentech Co-founder PhD and postdoc from UZH; research in Tokyo, London Steven H. Holtzman President and CEO, Decibel Therapeutics Former EVP, Biogen Andreas Emmenegger, CFO Former CFO Glycart, Finance Roles at Roche >20 years experience as CFO of private & listed companies and in fund raising, IPOs William Bill Lee EVP Research, Gilead Dr. Pamela Trail, CSO >30 years of experience in directing cancer drug discovery at leading global pharma companies 39 Petri Vainio Managing Director, Essex Woodlands Ventures
40 Key Figures FY2018 (CHF million, except per share and FTE data) FY 2018 FY 2017 change Revenues (9.6) Total expenses 1 (47.8) (45.9) (2.0) Operating result EBIT (37.4) (25.8) (11.6) Net financial result Net result (37.0) (25.4) (11.6) Basic net result per share (in CHF) (1.75) (1.22) (0.53) Net cash used in operations (42.5) (40.0) (2.5) Cash balance (incl. time deposits) as of Dec (42.1) Number of FTE s as of Dec Thereof non-cash costs of CHF 5.3mn in in FY2018 and CHF 5.0mn in FY Including CHF 9.8m short-term time deposits Note: Rounding differences may occur 40
41 Financial Guidance for Full-Year 2019 Total expenses of CHF million, of which around CHF 7 million non-cash effective costs Capital expenditures of ca. CHF 3 million No guidance on net cash flow; timelines and potential milestones payments with partnerships not disclosed Guidance subject to progress and changes of pipeline 41
42 Shareholder Structure Shareholder structure as of December 31, 2018 Highlights VC holdings halved vs. end 2016 to 23% 59% 23%* 18%* Listed on SIX Swiss Exchange (SIX: MOLN) Included in key indices: SPI, SPI Extra, SXI Life Sciences and SXI Bio+Medtech 21,228,593 shares outstanding Ca. CHF 405 million market cap. as of Dec. 31, 2018 Pre-IPO investors (4 VC's) Management, Board, Founders Others No lock-up restrictions in place Formal free float as per SIX definition: 84% * According to SIX Swiss Exchange Filings 42
43 Disclaimer This presentation is not an offer to sell or a solicitation of offers to purchase or subscribe for shares of Molecular Partners AG, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision. This presentation is not an offering circular within the meaning of Article 652a of the Swiss Code of Obligations, nor is it a listing prospectus as defined in the listing rules of the SIX Swiss Exchange AG or a prospectus under any other applicable laws. Copies of this presentation may not be sent to countries, or distributed in or sent from countries, in which this is barred or prohibited by law. This document is not a prospectus or a prospectus equivalent document and investors should not subscribe for or purchase any securities referred to in this document. This document does not constitute a recommendation regarding the shares. This presentation contains specific forward-looking statements, beliefs or opinions, including statements with respect to the product pipelines, potential benefits of product candidates and objectives, estimated market sizes and opportunities as well as the milestone potential under existing collaboration agreements, which are based on current beliefs, expectations and projections about future events, e.g. statements including terms like potential, believe, assume, expect, forecast, project, may, could, might, will or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Molecular Partners AG and investments and those explicitly or implicitly presumed in these statements. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these statements and forecasts. Past performance of Molecular Partners AG cannot be relied on as a guide to future performance. Forward-looking statements speak only as of the date of this presentation and Molecular Partners AG, its directors, officers, employees, agents, counsel and advisers expressly disclaim any obligations or undertaking to release any update of, or revisions to, any forward looking statements in this presentation. No statement in this document or any related materials or given at this presentation is intended as a profit forecast or a profit estimate and no statement in this document or any related materials or given at this presentation should be interpreted to mean that earnings per share for the current or future financial periods would necessarily match or exceed historical published earnings per share. As a result, you are cautioned not to place any undue reliance on such forwardlooking statements. Unless stated otherwise the information provided in this presentation are based on company information. This presentation is intended to provide a general overview of Molecular Partners AG s business and does not purport to deal with all aspects and details regarding Molecular Partners AG. Accordingly, neither Molecular Partners AG nor any of its directors, officers, employees, agents, counsel or advisers nor any other person makes any representation or warranty, express or implied, as to, and accordingly no reliance should be placed on, the accuracy or completeness of the information contained in the presentation or of the views given or implied. Neither Molecular Partners AG nor any of its directors, officers, employees, agents, counsel or advisers nor any other person shall have any liability whatsoever for any errors or omissions or any loss howsoever arising, directly or indirectly, from any use of this information or its contents or otherwise arising in connection therewith. The material contained in this presentation reflects current legislation and the business and financial affairs of Molecular Partners AG which are subject to change and audit. 43
44 Molecular Partners AG Wagistrasse Zürich-Schlieren Switzerland T IR Agenda March 15, 2019 Expected Publication of Annual Report 2018 April 16, 2019 Annual General Meeting May 9, 2019 Publication of Q1 Interim Management Statement 44
Molecular Partners: Building Tomorrow s Breakthroughs. Corporate Presentation Molecular Partners AG, Switzerland (SIX: MOLN) March 15, 2019
Molecular Partners: Building Tomorrow s Breakthroughs Corporate Presentation Molecular Partners AG, Switzerland (SIX: MOLN) March 15, 2019 1 Molecular Partners: A Swiss Biotech developing innovative protein
More informationMaking the DARPin Difference Reality for Patients
Making the DARPin Difference Reality for Patients Patrick Amstutz, CEO Presentation: Molecular Partners AG Cowen and Company Healthcare Conference - March 13 th 2018 2018 Molecular Partners AG Slide 1
More informationThe DARPin Difference
The DARPin Difference Offering Patients a New Dimension of Protein Therapeutics Sandra Dietschy, Manager Business & Pipeline Strategy Thomas Schneckenburger, IR Presentation at Investora Conference September
More informationMaking the DARPin Difference Reality for Patients
Making the DARPin Difference Reality for Patients Corporate Presentation of Molecular Partners AG, Switzerland (SIX: MOLN) August 30, 2018 2018 Molecular Partners AG Slide 1 Molecular Partners: Who We
More informationINTERIM MANAGEMENT STATEMENT Q3 2017
INTERIM MANAGEMENT STATEMENT Q3 2017 Significant progress across all clinical programs New pre-clinical immunooncology data to be presented during R&D Day in New York Research & Development highlights:
More informationMaking the DARPin Difference Reality for Patients
Making the DARPin Difference Reality for Patients Corporate Presentation of Molecular Partners AG, Switzerland (SIX: MOLN) June 4, 218 218 Molecular Partners AG Slide 1 Molecular Partners: Who We Are $
More informationMaking the DARPin Difference Reality for Patients
Making the DARPin Difference Reality for Patients Corporate Presentation of Molecular Partners AG, Switzerland (SIX: MOLN) January 22 nd 2018 2018 Molecular Partners AG Slide 1 Molecular Partners: Who
More informationThe DARPin Difference
The DARPin Difference Offering Patients a New Dimension of Protein Therapeutics Corporate Presentation of Molecular Partners AG, Switzerland (SIX: MOLN) March 2017 2017 Molecular Partners AG - 1 Disclaimer
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationLeading the Next Wave of Biotech Breakthroughs
Leading the Next Wave of Biotech Breakthroughs Corporate Extensive corporate assets Platforms Pipeline Partnerships Building a sustainable global business Platform licenses represent a source of non-dilutive
More informationNOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A. C5aR. NKp46 HALF-YEAR RESULTS. Tumor antigen KIR3DL2 CD39 MICA/B CD73 SEPTEMBER 18, 2017
NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A NKp46 C5aR Tumor antigen HALF-YEAR RESULTS KIR3DL2 MICA/B CD73 CD39 SEPTEMBER 18, 2017 Page 2 FORWARD LOOKING STATEMENT This document has been prepared by
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationBuilding a Premier Oncology Biotech
Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation
More informationInvestor presentation. Bioshares Biotech Summit July 2017
Investor presentation Bioshares Biotech Summit 2017 22 July 2017 1 Disclaimer Some of the information in this presentation may refer to Dimerix Limited ( Dimerix or the Company ) based on information available
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationCalliditas Therapeutics Q2 Report Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Calliditas Therapeutics Q2 Report 2018 Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation may contain certain
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationBuilding a Premier Oncology Biotech
Corporate Presentation Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO January 2019 Forward-Looking Statements All of the statements in this presentation that are not statements
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationBank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt. September 14, 2011
Bank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt Chairman of the Board of Management of Bayer HealthCare AG and Chairman of the Bayer HealthCare Executive Committee
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationInfinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results
Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results Heat Shock Protein 90 Program Continues to Advance Toward Potential Registration Trial CAMBRIDGE, Mass.,
More informationQ4 Report Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Q4 Report 2018 Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation has been prepared by Calliditas Therapeutics AB
More informationBuilding a Premier Oncology Biotech
Corporate Presentation Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO February 2019 Forward-Looking Statements All of the statements in this presentation that are not statements
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationTreatment of visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO):
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Treatment of visual impairment due to macular edema secondary to branch retinal
More informationTARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements
More informationFor personal use only
HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening
More informationInvestor Presentation
ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an
More informationMOLOGEN AG. Our research for you. Annual Results Analysts Call March 21, 2013
Our research for you. Annual Results 2012 Analysts Call March 21, 2013 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments,
More informationCOMPANY OVERVIEW. June CytomX Therapeutics, Inc.
COMPANY OVERVIEW June 2016 2016 CytomX Therapeutics, Inc. Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation may contain projections and other forward-looking
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationQ1 Results 2018 Webcast presentation 26 April 2018
Q1 Results 2018 Webcast presentation 26 April 2018 Disclaimer This presentation contains forward-looking statements, including (without limitation) statements concerning the progress of our clinical pipeline,
More informationSpectrum Pharmaceuticals
Spectrum Pharmaceuticals Joe Turgeon President and CEO June 2018 Investor Presentation 1 Safe Harbor Statement This presentation contains forward looking statements regarding future events and the future
More informationSavolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer
Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer Initiation of expanded Phase II trials in NSCLC triggers US$10 million milestone from AstraZeneca to Chi-Med New study
More informationPierre Legault CEO June 2, 2014
April 2012 Pierre Legault CEO June 2, 2014 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationBuilding a Premier Oncology Biotech
Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within
More informationBayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye in Wet Age-related Macular Degeneration
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye in Wet Age-related Macular Degeneration International
More informationSlide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
More informationCorporate Presentation. October 2017
AEPP Breakthrough technology for women s cancers Corporate Presentation October 2017 Oncolix 2017 1 Safe Harbor Certain of the statements and the projections set forth in this presentation constitute forward-looking
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More information9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO
9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO BERLIN, 13 NOVEMBER, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,
More informationAugust 7, Q Financial Results
August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationFor personal use only
Virtus Health (ASX. VRT) Sue Channon CEO and Glenn Powers CFO Navigating Future Growth, UBS Australasian Conference 7 November, 2016 DISCLAIMER 2 The material in this presentation has been prepared by
More informationJEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018
1 JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.
More informationCorporate Presentation March 2016
Corporate Presentation March 2016 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationCorporate Overview May 8, 2014
0 Corporate Overview May 8, 2014 NASDAQ: CRIS Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward-looking statements
More informationCompany overview. Highlights for the 1 st quarter 2018 (January-March)
Company overview Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The company is a leader in the rapidly developing field of
More informationNASDAQ: CYTR FIGHTING CANCER WITH CUTTING EDGE SCIENCE. Corporate Overview. July 2018
NASDAQ: CYTR Corporate Overview July 2018 CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationZealand Pharma A/S Interim report for Q (un-audited)
Company Announcement No. 12/2012 (un-audited) Net profit for the quarter of DKK 66 (EUR 9) million Important pipeline progress, and revenue from milestone payments of DKK 120 (EUR 16) million Cash and
More informationCorporate Presentation
Corporate Presentation March 2018 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements within the meaning of the United States Private Securities
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationi-bodies a new class of protein therapeutics to treat fibrosis
i-bodies a new class of protein therapeutics to treat fibrosis BIOSHARES JULY 2017 Sam Cobb, CEO and Managing Director AdAlta Limited (ASX:1AD) s.cobb@adalta.com.au Disclaimer Investment in AdAlta is subject
More informationSumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)
December 21, 2016 Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company) Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka,
More informationCIRCADIAN TECHNOLOGIES LIMITED ASX:CIR, OTCQX:CKDXY
1 AUSBIOTECH INVESTMENT SHOWCASE MELBOURNE NOVEMBER 2 2012 CIRCADIAN TECHNOLOGIES LIMITED ASX:CIR, OTCQX:CKDXY Robert Klupacs, CEO & Managing Director DISCLAIMER Investment in Circadian Technologies Limited
More informationMerrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference. February 7, 2007
Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference February 7, 2007 Information related to forward-looking statements This presentation includes forward-looking statements
More informationIpsen Acquisition of Clementia Pharmaceuticals. February 25, 2019
Ipsen Acquisition of Clementia Pharmaceuticals February 25, 2019 Disclaimer & Safe Harbor This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements,
More informationGSK Oncology R&D Update
GSK Oncology R&D Update Axel Hoos, MD Senior Vice President, Oncology R&D February 2019 Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements.
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationFOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE. Thursday, February 7, 2019
FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE Thursday, February 7, 2019 Today s Speakers Overview and Key Highlights Clay Siegall, President & CEO Financial Results and Guidance
More informationAviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES
Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about
More informationFormation Biologics. A clinical-stage biopharmaceutical company Lead program projected to achieve clinical validation in 2018
Formation Biologics A clinical-stage biopharmaceutical company Lead program projected to achieve clinical validation in 2018 Formation Biologics Corporate Summary Clinical-stage development company based
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
June 14, 2018 Committed to Transforming the Treatment Paradigm for Migraine Prevention September 6, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking
More informationSlide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationBayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationCorporate Presentation November Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation November 2015 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationInvestor Presentation
Investor Presentation June 2017 Joe Turgeon President and Chief Operating Officer Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance
More informationSpotlight on SF0166: topical eye droplet treatment for retinal diseases DME and wet-amd
Spotlight on SF0166: topical eye droplet treatment for retinal diseases DME and wet-amd Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More information34 th Annual J.P. Morgan Healthcare Conference
JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains
More informationObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update
ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update - All Three Development Compounds Progressing with Key Clinical Milestones Over the Next 12 Months - Geneva, Switzerland
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationIMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationImmunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma
PRESS RELEASE IMMUNOCORE LIMITED Immunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma (Oxford, UK, 16 April 2015) Immunocore Limited, a world-leading
More informationUnder the terms of the agreement, AVEO will receive an initial cash payment of $125 million, composed of a $75 million license fee and $50 million in
Astellas Pharma Inc. AVEO Pharmaceuticals Corporate Communications Investor Contact: Astellas Pharma Inc. Monique Allaire AVEO Pharmaceuticals +81(3)-3244-3201 (617) 299-5810 Media Contact: Dan Budwick
More informationFor personal use only
ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company s Annual General Meeting
More informationNewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results
July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationHALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More informationBank of America Merrill Lynch 2016 Health Care Conference
Bank of America Merrill Lynch 2016 Health Care Conference Dr. Steven Stein Chief Medical Officer David Gryska Chief Financial Officer May 11, 2016 Forward Looking Statements Except for the historical information
More informationMOLOGEN AG. Our research for you. German Equity Forum November 2012
Our research for you. German Equity Forum 12-14 November 2012 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as
More information